Intercept Pharma (ICPT) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cowen Reiterates Bullish View on Intercept Pharmaceuticals (ICPT) Ahead of Catalysts, Trims PT to $412
August 6, 2015 1:34 PM EDTCowen analyst Ritu Baral trimmed the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $412.00 (from $420.00) following Q2 results and update, but maintained an Outperform rating as the NASH trial heats up and the OCA for PBC launch gears up.
Baral... More
Janney Capital Maintains Bullish Stance on Intercept Pharmaceuticals (ICPT) Following Q2 Update
August 6, 2015 7:45 AM EDTJanney Capital analyst Chiara Russo reiterated a Buy rating and $363 fair value target on Intercept Pharmaceuticals (NASDAQ: ICPT) following Q2 results and update.
Russo commented, "In 2Q15, ICPT delivered on several important milestones, including the finalization of its Phase 3 NASH... More
